Back to Search
Start Over
FTY720 for cancer therapy (Review).
- Source :
-
Oncology reports [Oncol Rep] 2013 Dec; Vol. 30 (6), pp. 2571-8. Date of Electronic Publication: 2013 Oct 01. - Publication Year :
- 2013
-
Abstract
- 2-Amino-2-[2-(4-octylphenyl)]-1,3-propanediol hydrochloride (FTY720) is a potent immunosuppressant which has been approved by the Food and Drug Administration (FDA) as a new treatment for multiple sclerosis. As an immunosuppressant, it displays its anti-multiple sclerosis, immunosuppressive effects by activating sphingosine-1-phosphate receptors (S1PRs). In addition to the immunosuppressive effects, FTY720 also shows preclinical antitumor efficacy in several cancer models. In most cases, phosphorylation of FTY720 is not required for its cytotoxic effect, indicating the involvement of S1PR-independent mechanisms which are starkly different from the immunosuppressive property of FTY720. In the present study, we reviewed the rapidly advancing field of FTY720 in cancer therapy as well as some molecular targets of the unphosphorylated form of FTY720.
- Subjects :
- Fingolimod Hydrochloride
Humans
Multiple Sclerosis drug therapy
Multiple Sclerosis pathology
Neoplasms genetics
Neoplasms pathology
Phosphorylation
Receptors, Lysosphingolipid genetics
Sphingosine therapeutic use
United States
United States Food and Drug Administration
Immunosuppressive Agents therapeutic use
Neoplasms drug therapy
Propylene Glycols therapeutic use
Receptors, Lysosphingolipid metabolism
Sphingosine analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 1791-2431
- Volume :
- 30
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Oncology reports
- Publication Type :
- Academic Journal
- Accession number :
- 24100923
- Full Text :
- https://doi.org/10.3892/or.2013.2765